Entrada Therapeutics Inc (TRDA) Stock Price, Quote & News

Company Profile

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versa...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 520 9158

Website: www.entradatx.com

Address:

One Design Center Place, Suite 17- 500, Boston, United States

DarkVantage Feb. 18 at 9:01 AM

$TRDA Development-stage biotech where trial readouts are the sole driver; price action will front-run data long before fundamentals change.

0 · Reply

TheTradeXchange Feb. 17 at 12:02 PM

$TRDA - Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

0 · Reply

OfficialStocktwitsUser Feb. 12 at 12:21 PM

$TRDA RSI: 43.44, MACD: 0.0810 Vol: 0.48, MA20: 11.07, MA50: 10.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

1 · Reply

ShelleyGardner428 Feb. 11 at 5:16 PM

$TRDA Entrada Therapeutics; biotech (Duchenne MD); early-stage; platform; partnered; binary catalysts.

0 · Reply

buyandsold Jan. 28 at 6:18 PM

$TRDA $CYTK green today deserves a rocket ship emoji

0 · Reply

OfficialStocktwitsUser Jan. 26 at 7:31 PM

$TRDA RSI: 56.77, MACD: 0.3150 Vol: 0.51, MA20: 10.60, MA50: 10.30 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

kubota2323 Jan. 22 at 3:14 PM

$TRDA added/adding

0 · Reply

ppl_first Jan. 21 at 8:00 PM

$TRDA Platform with high-quality human data and strategic partnerships. Valuation reflects platform skepticism, not asset failure; commercial clock not yet applicable.

0 · Reply

buyandsold Jan. 17 at 6:39 PM

$TRDA the last 3 months have seen 75% gains during a period of no news no catalysts. The future is bright according to the buyers.

0 · Reply

buyandsold Jan. 9 at 8:18 PM

$TRDA need to reclaim 11. I will sell at 50

3 · Reply

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

Feb 4, 2026, 7:00 AM EST - 19 days ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

Jan 15, 2026, 12:45 AM EST - 5 weeks ago

Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 7:00 AM EST - 6 weeks ago

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

Dec 17, 2025, 7:00 AM EST - 2 months ago

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 4, 2025, 4:30 PM EST - 2 months ago

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 17, 2025, 9:30 AM EST - 3 months ago

Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts

Nov 6, 2025, 7:00 AM EST - 3 months ago

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

Sep 25, 2025, 2:57 PM EDT - 5 months ago

Entrada Therapeutics, Inc. - Special Call

Sep 5, 2025, 7:00 AM EDT - 6 months ago

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Jun 3, 2025, 7:00 AM EDT - 9 months ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

BIIB

May 28, 2025, 7:00 AM EDT - 9 months ago

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 8, 2025, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Feb 19, 2025, 11:31 AM EST - 1 year ago

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Feb 3, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Jan 30, 2025, 4:05 PM EST - 1 year ago

Azenta Announces the Election of Dipal Doshi to its Board of Directors

AZTA

Dec 18, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Sep 17, 2024, 8:30 AM EDT - 1 year ago

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Jun 24, 2024, 7:15 AM EDT - 1 year ago

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Jun 24, 2024, 6:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 16, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 7, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Mar 13, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Nov 22, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Aug 8, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 6:39 PM EDT - 2 years ago

Entrada Therapeutics: Early Stage But Interesting

Jun 6, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports First Quarter 2023 Financial Results

Apr 4, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Mar 29, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Mar 6, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 27, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Dec 19, 2022, 4:30 PM EST - 3 years ago

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Dec 8, 2022, 8:24 AM EST - 3 years ago

Entrada Therapeutics shares jump on collaboration with Vertex

Dec 8, 2022, 7:00 AM EST - 3 years ago

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

VRTX

Nov 7, 2022, 7:00 AM EST - 3 years ago

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Aug 30, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

DarkVantage Feb. 18 at 9:01 AM

$TRDA Development-stage biotech where trial readouts are the sole driver; price action will front-run data long before fundamentals change.

0 · Reply

TheTradeXchange Feb. 17 at 12:02 PM

$TRDA - Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

0 · Reply

OfficialStocktwitsUser Feb. 12 at 12:21 PM

1 · Reply

ShelleyGardner428 Feb. 11 at 5:16 PM

$TRDA Entrada Therapeutics; biotech (Duchenne MD); early-stage; platform; partnered; binary catalysts.

0 · Reply

buyandsold Jan. 28 at 6:18 PM

$TRDA $CYTK green today deserves a rocket ship emoji

0 · Reply

OfficialStocktwitsUser Jan. 26 at 7:31 PM

0 · Reply

kubota2323 Jan. 22 at 3:14 PM

$TRDA added/adding

0 · Reply

ppl_first Jan. 21 at 8:00 PM

$TRDA Platform with high-quality human data and strategic partnerships. Valuation reflects platform skepticism, not asset failure; commercial clock not yet applicable.

0 · Reply

buyandsold Jan. 17 at 6:39 PM

$TRDA the last 3 months have seen 75% gains during a period of no news no catalysts. The future is bright according to the buyers.

0 · Reply

buyandsold Jan. 9 at 8:18 PM

$TRDA need to reclaim 11. I will sell at 50

3 · Reply

ppl_first Jan. 7 at 11:25 PM

$TRDA picked up more today at 9.90

0 · Reply

OfficialStocktwitsUser Dec. 29 at 10:57 AM

$TRDA RSI: 51.47, MACD: 0.5017 Vol: 0.44, MA20: 10.62, MA50: 8.84 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MastMeteorology Dec. 26 at 5:40 PM

$TRDA Price action signals that reliability now matters more than headline momentum. Governance alignment should reduce uncertainty over time. Risk compresses once delivery patterns become predictable. Upside remains tied to tangible progress, not assumptions.

0 · Reply

ppl_first Dec. 24 at 3:56 PM

$TRDA is a pre-binary upswing candidate because it has catalysts approaching, cash runway, and future binary decisions, albeit not near-term. Great time to accumulate the dips.

0 · Reply

SuperGreenToday Dec. 15 at 11:20 AM

$TRDA Share Price: $11.09 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $0.72 – $0.89 Target Zone: $1.29 – $1.57 Potential Upside: 68% ROI Time to Expiration: 184 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

MrEsKurr Dec. 9 at 12:27 AM

$TRDA not sleeping on this one it looks tidy and ready to go.

1 · Reply

NorthStarStats Nov. 17 at 7:16 PM

$TRDA sold this bad pickle this morning. Not looking positive short term.

1 · Reply

NorthStarStats Nov. 13 at 6:56 PM

$TRDA finally making money here

0 · Reply

d_risk Nov. 6 at 4:51 PM

$TRDA - Entrada Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors TRDA’s latest 10-Q risk factors spotlight the capital-intensive, early-stage nature of its biopharma pipeline, heavy reliance on unproven EEV technology, major funding and dilution risks, expanded regulatory and clinical trial hurdles, new legal and tax uncertainties, intensified competition for talent, and a surge in market, IP, compliance, and macroeconomic risks—plus new warnings on public health crises, ESG pressures, and federal government shutdown impacts. #Biopharma #MarketVolatility #RegulatoryHurdles #FundingRisk #EEVTechnology 🟢 Added 🟠 Removed https://d-risk.ai/TRDA/10-Q/2025-11-06

0 · Reply

Goosem4n Oct. 15 at 1:26 AM

$TRDA healthy pullback. Let's see where it goes next.

0 · Reply

Market Cap	431.49M
Revenue (ttm)	210.78M
Net Income (ttm)	65.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	31.14%
Debt to Equity Ratio	0.00

Volume	135,000
Avg Vol	213,370
Day's Range	N/A - N/A
Shares Out	38.22M
Stochastic %K	85%
Beta	-0.12
Analysts	Strong Sell
Price Target	$18.50